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Edited by Sandro SonninoAbstract Glycopeptides derived from human transferrin were
exhaustively analyzed by matrix-assisted laser desorption ioni-
zation and electrospray ionization mass spectrometry (MS).
Both MS techniques clearly revealed the sequences of and the
attachment sites of bi-antennary complex-type oligosaccharides,
at both Asn432and Asn630, both of which are located in a well-
known motif for N-glycosylation, Asn-Xaa-Ser/Thr, but also at
Asn491in the Asn-Xaa-Cys motif. The latter has been reported to
be a minor N-glycosylation site in several glycoproteins. The
relative abundance of this abnormal glycosylation was estimated
to be approximately 2 mol% of the transferrin preparation used
in this study.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It is widely recognized that the sugar chains of glycoproteins
contribute signiﬁcantly to the functional properties of glyco-
proteins, which include their stability, biological activity, and
binding aﬃnity, even though little is known concerning their
biological functions. The importance of carbohydrate moieties
on glycoproteins has increased along with the maturation of
the protein sequence database. However, the characterization
of oligosaccharide structures of glycoproteins remains a chal-
lenge, owing to their complexities, as represented by the het-
erogeneity, the number of isomers possible and branching
structures.
Mass spectrometry (MS) has become a powerful and useful
tool for the analysis of complex structures of carbohydrates
such as those linked to a glycoprotein and is capable of re-
vealing the molecular mass and sequence of the constituent
sugar units. Such capabilities have been gained since the ad-* Corresponding author. Fax: +816-68794312.
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[1] and matrix-assisted laser desorption ionization (MALDI)
[2], both of which allow for the direct measurement of rela-
tively large carbohydrates and glycoproteins with molecular
masses over 50 000 Da and provide suﬃcient molecular ions
that are amenable to a structural analysis using tandem mass
spectrometry (MS/MS). In spite of the increasing MS capa-
bilities for carbohydrate analysis, it is still not suﬃcient to
permit a precise proﬁle of the oligosaccharides of a glycopro-
tein to be acquired. One major issue to be overcome is the
diﬃculty in isolating individual glycopeptides carrying single
glycosylation from a glycoprotein, which permits the site-
speciﬁc analysis of carbohydrate moieties, an issue that needs
to be clariﬁed for a multiply-glycosylated protein.
In this study, we report on the use of MALDI- and ESI-MS/
MS to analyze glycopeptides derived from a commercially
available human transferrin, the carbohydrate moieties of
which are well known to be a bi-antennary complex-type oli-
gosaccharide and which are located at Asn432 and Asn630, both
of which are involved in the consensus sequence (Asn-Xaa-Ser/
Thr) of N-glycosylation [3–5]. During the course of the anal-
ysis, we detected, for the ﬁrst time, glycosylation at Asn491 as a
minor component, in addition to the above two glycosylation
sites, which are located in the sequence, an Asn-Xaa-Cys
motif, which has been reported to be a minor N-glycosylation
site [6–13]. Furthermore, ESI-MS/MS of this glycosylated
peptide (Ile490–Lys508) indicated that it is a bi-antennary
complex-type oligosaccharide.2. Materials and methods
2.1. Materials
Human transferrin (T2252) and a-cyano-4-hydroxy cinnamic acid
(CHCA) were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Achromobacter lyticus protease I (lysylendopeptidase
(LEP)),18O-normalized water (93.8 atom%), and Peptide-N-glycosi-
dase F (PNGase F), which cleaves the b-aspartylglycosylamine linkage
of Asn-linked carbohydrate, were obtained from Wako Pure Chemical
Industries (Osaka, Japan), ISOTEC Inc. (Miamisburg, OH, USA), and
New England Bio-laboratory (Beverly, MA), respectively.
2.2. Preparation of glycopeptides
Human transferrin (6 nmol) was dissolved in 100 ll of 250 mM Tris–
HCl (pH 8.5) containing 6 M guanidine hydrochloride and 2 mM
EDTA, and incubated at 37 C for 30 min. The protein was treated
with a 50-fold excess of DTT (1 mg) to reduce Cys residues at room
temperature for 3 h in an atmosphere of N2 followed by incubation
with 2.5-fold excess of monoiodoacetic acid, relative to the amount of
DTT. The reaction was allowed to proceed for 30 min at room tem-
perature in the dark. The solution was dialyzed against distilled water
and lyophilized. The resulting S-carboxymethylated human transferrinblished by Elsevier B.V. All rights reserved.
Fig. 1. RP-HPLC of a LEP digest of carboxymethylated human transferrin. The observed MHþ values for each fraction are assigned to the sequence
(see Fig. 2, Table 1). Fractions 18 and 22 contained glycopeptides and were subjected to further re-chromatography (Fig. 4(a)).
Fig. 2. Amino acid sequence of human transferrin. Double-arrowhead
solid lines and the numbers in parentheses indicate the LEP peptides
obtained in Fig. 1 (see Table 1). Amino acids in boldface correspond to
the glycopeptides found in fractions 18 and 22. Asn (N) with ﬁlled
circles denote the N-glycosylation sites veriﬁed by ESI-MS/MS (see
Fig. 5).
Table 1
Summary of observed masses of the LEP peptides of human trans-
ferrin and their corresponding theoretical masses
Fraction
no.a
Observed
m/z
Theoretical
m/z
Position
1 –b – –
2 – – –
3 1209.5(m)c 1209.5(m) 38–46
4 1175.7(m) 1175.6(m) 660 668
5 913.2(m) 913.5(m) 324–331
6 – – –
7 – – –
8 2151.0(m) 2151.0(m) 259–278
9 – – –
10 978.2(m) 978.5(m) 216–225
11 1727.7(m) 1727.7(m) 385–399
12 1674.7(m) 1674.8(m) 24–37
1437.7(m) 1437.7(m) 363–373
13 1000.3(m) 1000.5(m) 669–676
14 1416.6(m) 1416.7(m) 47–60
15 1096.4(m) 1096.6(m) 98–107
16 1281. 5(m) 1281.5(m) 374–384
17 1273.6(m) 1273.7(m) 226–236
18 1249.3(m) 1249.6(m) 454–464
3391.7(a)d 3393.5 (a) Glycopeptide (421–433)
3682.1(a) 3684.7(a) Glycopeptide (421–433)
4175.0(a) 4176.2(a) Glycopeptide (490–508)
4465.3(a) 4467.5(a) Glycopeptide (490–508)
19 2011.0(m) 2011.0(m) 237–252
2742.3(m) 2742.3(m) 237–258
20 1276.6(m) 1276.6(m) 300–310
21 3999.7(a) 4000.5(a) 577–610
1786.8 (m) 1786.8(m) 684–698
22 2260.0(m) 2260.0(m) 490–508
5261.5(a) 5261.5(a) Glycopeptide (619–646)
5551.8(a) 5552.8(a) Glycopeptide (619–646)
23 2073.0(m) 2072.9(m) 434–452
24 1566.7 (m) 1566.8(m) 647–659
25 1629.6(m) 1629.8(m) 108–121
26 1913.8(m) 1913.9(m) 531–546
27 – – –
28 3340.3(a) 3340.7(a) 332–359
29 3637.3(a) 3639.2(a) 136–167
30 4995.2(a) 4997.5(a) 168–212
31 2070.1(m) 2070.0(m) 279–295
32 3858.0(a) 3858.3(a) 62–97
33 4936.4(a) 4936.6(a) 62–107
aNumbers in the chromatogram in Fig. 1.
bNot identiﬁed.
c (m), Monoisotopic mass.
d (a), Average mass.
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sylendopeptidase (E/S¼ 1/100) and incubated for 10 h at 37 C.
2.3. Reverse-phase-HPLC
The peptides produced by the LEP digestion were separated by re-
verse-phase (RP)-HPLC using a Develosil 5C18-UG column (4.6 150
mm, Nomura Chemicals, Aichi, Japan), using a Waters model LC204
system (Milford, MA). A linear gradient between solvent A (0.1%
triﬂuoroacetic acid (TFA) in water) and solvent B (0.1% TFA in
acetonitrile) was used for the separation. The peptides were eluted by
increasing solvent B from 5% to 60% over a 55 min period at a
ﬂow rate of 1.0 ml/min. The eluates were monitored at both 214 and
280 nm using Waters model 441 and 440 UV absorbance detectors,
respectively.
2.4. PNGase F treatment of glycopeptides
The glycopeptides were dissolved in 100 mM NH4HCO3 in 40
atom% H2
18O, and treated with 1 ll of a PNGase F solution con-
taining 500 units for 5 h at 37 C. Deglycosylated peptides were pu-
riﬁed by RP-HPLC using the same conditions as the above, quantiﬁed
by amino acid analysis, and examined by MALDI-MS and ESI-MS/
MS.
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MALDI-MS spectra were obtained on a Voyager Elite XL time-
of-ﬂight mass spectrometer equipped with a delayed-extraction sys-
tem (Applied Biosystems, Framingham, MA, USA) with a ﬂight
pass of 6.5 meters in the reﬂectron mode. The samples were mixed
with the matrix solution, the supernatant of a 50% acetonitrile so-
lution saturated with CHCA, and then air dried on the ﬂat surface
of a stainless steel plate. Ions were generated by irradiating the
sample area with the output of a N2 laser at a wavelength of 337
nm and accelerated at a 20 or 25 kV potential in the ion source with
a delay of 200 ns. Mass calibration was carried out using a mixture
of angiotensin I and insulin (1/5, mol/mol) for measurements of
peptides.
2.6. Nano-ﬂow electrospray ionization tandem mass spectrometry
Low-energy collision-induced dissociation (CID) MS/MS was
carried out on a Q-TOF mass spectrometer (Micromass, Manches-
ter, UK), which is a hybrid quadrupole orthogonal acceleration
tandem mass spectrometer ﬁtted with a Z-spray nano-ﬂow electro-
spray ion source. Samples were dissolved in acetic acid/acetonitrile/
water (1/50/50, v/v/v) at the concentration of 500 fmol/ll and 2 ll
of this solution was loaded on a nano-ﬂow glass-capillary prior to
analysis. A potential of 1.0–1.5 kV was applied to the glass-capillary
tip in the ion source, which resulted in a ﬂow rate of about 10–20
nl/min into the analyzer. Mass calibration was carried out using the
cluster ions derived from NaI. MS/MS data were processed by a
maximum entropy data enhancement program, MaxEnt3 (Micro-
mass), which is capable of deconvoluting a spectrum where peaks in
a variety of charge states are present, thus producing a simpliﬁedFig. 3. MALDI-MS spectrum of fraction 18 in Fig. 1. The observed
glycopeptides turned out to contain NeuNAc. The measurement was
operated in the negative-ion mode.
Fig. 4. Re-chromatograms of fraction 18 in Fig. 1 before (a) and after (b) PN
and 2 in (b). Fraction 18 was treated with PNGase F in 40 atom% H2
18O (see
in (b) indicate the partial incorporation of 18O atoms into these two peptidespectrum consisting only of monoisotopic peaks in a single charge
state.3. Results and discussion
Nano-ﬂow ESI-MS of intact transferrin predominantly gave
the molecular mass (79 560) (data not shown), which was in
agreement with the theoretical value calculated for the sum
(79 556) of the protein moieties (75 144) and two oligosaccha-
ride chains (complex bi-antennary type (2206 Da)2). In ad-
dition, the spectrum indicated that the protein used was the
fully glycosylated form with the above oligosaccharides at two
potential sites, in which sialic acids were attached to the non-
reducing termini. To conﬁrm these glycosylation sites, carbo-
xymethylated transferrin, treated with LEP, was subjected to
RP-HPLC (Fig. 1). The peptides eluted were measured by both
positive-ion and negative-ion mode MALDI-MS. As the re-
sult, the observed molecular masses could cover ca. 76% of the
entire sequence including the two glycosylation sites (Fig. 2,
Table 1). In addition, negative-ion MALDI-MS of fraction 18
revealed two glycopeptides having m/z 3682.1 and 4465.3
(Fig. 3). While the former value corresponds to one of the
known glycopeptides, the latter could not be assigned to any
peptide expected from the sequence. However, the fact that the
ion at m/z 4465.3 was observed with a satellite ion at m/z
4175.0, diﬀerence in mass (290.3 Da) of which was also
observed for the ion at m/z 3682.1, strongly suggested the
presence of a sialic acid residue in this peptide, since the non-
reducing terminal sialic acid in an oligosaccharide tends to be
partially cleaved oﬀ, especially under conditions used in
MALDI-MS measurements.
To determine the amino acid sequence and glycosylation site
of the newly found glycopeptide, fraction 18, treated with
PNGase F in a buﬀer containing 40 atom% H2
18O, was sub-
jected to RP-HPLC (Fig. 4(b)), which gave two new peak
fractions 1 and 2 after the deglycosylation. MALDI-MS ofGase F treatment, and MALDI-MS (c) of newly emerged fractions 1
Section 2). Isotopic ion distributions obtained for the fractions 1 and 2
s (see Section 3).
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(Fig. 4(c)), respectively, both of which are deﬁcient in mass by
2206 Da (corresponding to the residual mass of a sialylated
complex-type bi-antennary oligosaccharide) from each of the
original glycopeptides. ESI-MS/MS of these deglycosylated
peptides revealed not only the amino acid sequences, Cys421–
Lys433 (MHþ:1478.6) and Ile490–Lys508 (MHþ:2261.1) (upper
panel of Fig. 5), but also the N-glycosylation sites at Asn432
and Asn491 in the sequence, based on the fact that these Asn
residues were converted to Asp stamped with18O atoms at the
b-carboxyl groups during the hydrolysis of the glycosidic
bonds in the H2
18O buﬀer with PNGase F (see y0017 and y0018
ions, the latter of which contained the converted Asp residue
and was observed as a doublet signal with a spacing of 2 u in
the lower panel of Fig. 5) [14]. As a result, glycosylation at
Asn432 could be conﬁrmed to be one of the two known gly-
cosyalation sites, whereas, Asn491, located in the Asn-Xaa-CysFig. 5. Low-energy CID ESI-MS/MS spectrum from [M + 3H]3þ at m/z 754.
ions in the raw data were transformed to single-charged ones using MaxEnt3
software aid for de novo sequencing by MS/MS (http://www.protein.osaka-u
on bn and yn ions, where n denotes the arbitrary positions counted from the
upon low-energy CID. Amino acids in three-letters in the spectrum denote im
at the b-carboxyl group. The arrows ( ) show the sequences from the N term
with previous work [17].motif, a minor glycosylation site of a glycoprotein, was a novel
glycosylation site, which has not been reported in human
transferrin to date. Based on the absorbance at 214 nm and an
amino acid analysis of fraction 1 in Fig. 4(b) in regard to the
non-glycosylated form with the same sequence (Ile490–Lys508)
eluting as fraction 22 in Fig. 2, the degree of the glycosylation
at this Asn491 was estimated to be ca. 2 mol%.
Finally, in order to characterize the oligosaccharide struc-
ture attached to Asn491, the glycopeptide observed at m/z
4465.3 in Fig. 3 was directly subjected to low-energy CID
ESI-MS/MS, obtained from the quadruply-charged precursor
ion [M + 4H]4þ at m/z 1117.0. Fig. 6 shows the spectrum, as
processed using MaxEnt3 (see Section 2), based on the raw
spectrum. The oxonium ions in the low mass region were
useful for elucidating the outer non-reducing terminal struc-
ture involving a sialic acid. The ions observed in the high
mass region, whose positive charges reside in the peptide3 of a deglycosylated peptide of fraction 1 in Fig. 4b. Multiple-charged
(see Section 2). The MS/MS spectrum was interpreted by ‘‘SeqMS’’, a
.ac.jp/rcsfp/proﬁling) [16]. The sequence was constructed mainly based
N and C terminus, which were produced by cleavage of peptide bonds
monium ions. Asp* indicates an Asp residue partially labeled with 18O
inus based on yn ions. The nomenclature of these ions is in accordance
Fig. 6. Low-energy CID ESI-MS/MS spectrum from [M + 4H]4þ at m/z 1117.0 for the glycopeptide of fraction 18 in Fig. 1. Multiple-charged ions in
the raw data were transformed to single-charged ones using MaxEnt3. The arrows ( and!) indicate the carbohydrate sequences from the non-
reducing termini based on the ions produced upon the cleavage of glycosidic bonds (see Section 3). One of the possible assignments of the observed
masses (monoisotopic) to the carbohydrate structure is depicted.
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readily revealed the relative alignment of the constituent
sugars from the non-reducing termini. In addition, informa-
tion on the degree of branching in the non-reducing termini
could be obtained through observing the overlapped signals
at m/z 4173.9 and 3882.7, and 4173.9 and 4011.8, the diﬀer-
ences of which correspond to N-acetyl-neuraminic acid (Ne-
uNAc) and a hexose, respectively, which resulted from the
truncation of the non-reducing terminal residues from either
of the two branches [15]. It is noteworthy that the low-energy
CID of a glycopeptide, even with a high-molecular mass over
4 kDa, provides a simple fragmentation pattern that pre-
dominantly arises from the cleavage of glycosidic bonds and
permits the direct structural analysis of the sugar moiety of a
glycopeptide, while the fragmentation of the peptide portion
is poor.
Since Bause and Legle [6] ﬁrst demonstrated the Asn-Xaa-
Cys motif for N-glycosylation by using several synthetic pep-tides in 1981, as far as we are aware, N-glycosylation in the
Asn-Xaa-Cys motif, even including the case of the minor
components in glycoproteins, has been found in only ﬁve types
of glycoproteins [7–13]. The glycosylation in this motif of
human transferrin, even as a minority, is suggestive of some
functional role of this glycosylation in vivo but it might rep-
resent a side-product that is formed uniquely in human
transferrin during its biosynthesis. It will be interesting to
pursue this minor structural alteration in human blood, which
might lead to an understanding of the physiological role of this
minor glycosylation in transferrin. These studies are currently
under way.
The glycopeptides were successfully analyzed by MALDI-
MS and ESI-MS/MS, and provided relevant structural data
on the sugar moieties present. The peptide portion, which
retains a positive charge in a positive-ion-mode measurement,
not only permits the highly sensitive detection of glycopep-
tides, with the actual sample consumption in an MS/MS study
56 Y. Satomi et al. / FEBS Letters 576 (2004) 51–56at the sub-picomole level, but also provides a useful structural
stamp of a sugar moiety upon low-energy CID albeit the
peptide portion fragments poorly. In addition, MS/MS se-
quencing of a peptide labeled with 18O at N-glycosylation
sites arguably provides a powerful analytical method for the
site-speciﬁc characterization of carbohydrates in a glycopro-
tein. The above MS-based techniques, used for the analysis of
glycopeptides, permitted the detection and characterization of
the minor glycosylation at Asn-Xaa-Cys motif in human
transferrin.
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